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lants (LA-STIM) in adults with ADHD using Medicaid.
METHODS: Data were from the IMS Health LRx Database.
Patients covered by Medicaid age ≥ 18 years were selected if they
initiated treatment with an ADHD medication categorized as
ATX, any STIM, or LA-STIM between January 2005 and
December 2005. Initiation was deﬁned as ﬁrst use of a medica-
tion preceded by 120 days without a prescription in the same
category. Contrasts of most-recent initiations of ATX vs. LA-
STIM or ATX vs. LA-STIM, were modeled via stepwise logistic
regression. Factors considered were age, gender, prior ADHD
medications, initiation type (treatment naïve, switch, add-on,
reintroduction), concomitant medications, provider specialty,
and line of therapy. RESULTS: A total of 8672 patients (58.04%
female) most recently initiated treatment with ATX, 27,574
(59.72% female) with STIM, and 15,958 (57.02% female) with
LA-STIM. Patients who were more likely to initiate ATX than
STIM (lower conﬁdence bound of adjusted odds ratios > 1) were
males, naïve to therapy, or had taken different ADHD medica-
tions in history prior to the current initiation, had prescriptions
from primary care physicians or nurse practitioners, had pre-
vious use of ATX, or had concomitant use of antidepressants,
antimanics, antipsychotics, anticonvulsants, or sleep aids. 
Conversely, STIM initiation was more likely for patients switch-
ing or being reintroduced to therapy, patients with prior use of
stimulant, having concomitant use with anxiolytics, or receiving
their prescription from neurologists. The model factors selected
for initiation of ATX vs. LA-STIM were consistent with those
for the comparison with STIM. CONCLUSION: The factors sig-
niﬁcantly associated with initiation of ATX vs. STIM or LA-
STIM suggest that therapy with ATX and STIM are addressing
different patient treatment needs. The ﬁndings suggest that 
ATX is preferentially prescribed for patients with psychiatric
comorbidities.
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OBJECTIVES: To model disease progression across multiple
domains in Alzheimer’s disease (AD) patients treated with a
cholinesterase inhibitor in clinical practice. METHODS: 435 AD
patients starting treatment with donepezil in 11 centers in
Sweden were followed up to 3 years. In 6-month intervals data
was collected on cognitive function (ADAS-Cog) physical func-
tion (IADL and PSMS scales), care setting and resource utiliza-
tion. Regression modelling was used to identify determinants of
disease progression rates and to establish equations predicting
progression across multiple domains. A dynamic panel approach
was used to model the 6 months change in cognitive function.
For physical function a random-effects model was ﬁtted using
ADAS-cog and lagged ADAS-cog as explanatory variables. In
both models other patient characteristics (e.g. sex, age, disease
duration and ApoE-genotype) were included when signiﬁcant.
RESULTS: The progression in ADAS-cog was estimated to
increase with higher progression in the previous 6 months
period, i.e. a one point higher progression in the previous period
would translate into 0.4 points higher progression in the present
cycle. Also, patients having at least one ApoE ε2 but no ApoE
ε4 allele were estimated to have about 2 points higher progres-
sion. Both IADL and PSMS scores were estimated to decrease
with higher present and lagged ADAS-cog scores (between 0.03
and 0.06 points for each ADAS-cog point) and higher disease
duration (0.14 to 0.2 points for each year). Also, male patients
were estimated to have 0.46 points lower IADL scores. CON-
CLUSION: The estimated regression functions can be used in a
regression model for simulation of long term disease progression.
Adding treatment effects and resource utilization linked to
disease severity this enables a dynamic framework for economic
evaluation of any treatment intervention.
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OBJECTIVES: Evaluate persistence and compliance patterns
with once-daily galantamine ER vs. twice-daily galantamine IR
and with galantamine ER vs. twice-daily rivastigmine in an
employer-based retiree health beneﬁt claims database.
METHODS: Data were obtained from a 9 million member
health beneﬁt claims database. Patients > 60 years with at least
one claim for galantamine ER, IR, or rivastigmine during the
period 1/1/05–2/28/06 were eligible, with the ﬁrst prescription
as the index event. Patients had 6 months continuous enrollment
pre- and post-index date. Galantamine ER patients were
matched up to 1 : 3 to IR and rivastigmine patients based on
propensity for galantamine ER therapy. Demographic and clini-
cal characteristics were evaluated pre- and post- propensity
matching using descriptive statistics for matched-pairs designs
(e.g., t-tests, ÷2 tests). Persistence was evaluated across matched-
pair sets by measuring duration of continuous therapy from
index date to a gap of more than twice the days supplied for the
previous reﬁll. Compliance with each treatment was assessed
using medication possession ratio (MPR), calculated as total
days supplied divided by total follow-up duration (180 days).
Wilcoxon signed rank tests were performed to compare persis-
tence and compliance measures for each matched-pair set.
RESULTS: The study included 743 galantamine ER versus 1611
IR and 812 galantamine ER versus 1712 rivastigmine users.
Demographic characteristics were similar between study groups.
Mean age was 78.9 years, 55% were women, and 99% were
institutionalized. Mean 6-month follow-up persistency rates
were longer for galantamine ER versus IR (136.2 vs 128.7 days;
p = 0.001) and for galantamine ER vs rivastigmine (135.1 vs
130.1 days; p = 0.029). Mean 6-month follow-up MPR was
higher for galantamine ER vs IR (0.60 vs 0.55; p < 0.01) and
trended higher for galantamine ER vs rivastigmine (0.60 vs 0.58;
p = 0.083). CONCLUSION: Our ﬁndings suggest once-daily
galantamine ER is associated with greater persistence and com-
pliance versus galantamine IR or rivastigmine.
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OBJECTIVES: Among the challenges in assessing persistence
with medication time to all-cause discontinuation with pharmacy
claims data are the potential variations in persistence deﬁnitions
and data-cutting criteria. This study compared persistence on
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atypical antipsychotics (olanzapine, risperidone, quetiapine, and
ziprasidone) using different deﬁnitions of persistence and data-
cutting criteria to assess their impact on the results and conclu-
sions. METHODS: Using the Pennsylvania Medicaid database
(January 1999–June 2003), patients diagnosed with schizophre-
nia, aged 18–64 who initiated an antipsychotic of interest after
a 3-month period without the index drug were identiﬁed. A treat-
ment episode was deﬁned as the period from the initiation date
of index medication to the ﬁrst medication gap. To assess the
effect of methodological changes on study outcomes three
methodologies were implemented: 1) 30- vs. 90-day gap to deﬁne
treatment discontinuation; 2) multi-episode vs. ﬁrst- or last-
episod; and 3) 1-year ﬁxed study duration. RESULTS: Using a
30-day gap to deﬁne treatment discontinuation, 43,491 treat-
ment episodes were identiﬁed (olanzapine = 16,709, risperidone
= 14,847, quetiapine = 8648, ziprasidone = 3287) for 24,365
patients. Average duration of these episodes was 211, 197, 180,
130 days, respectively for olanzapine, risperidone, quetiapine,
and ziprasidone and increased to 253, 236, 201, and 144 days
respectively using the last episode approach. Imposing a ﬁxed 1-
year study duration effectively truncated the longer treatment
episodes and had a different impact on the persistence of olan-
zapine (190 days), risperidone (183 days), quetiapine (170 days),
and ziprasidone (143 days). Similar patterns were observed using
a 90-day gap criteria. CONCLUSION: In claims database
studies, the approaches used to deﬁne persistence and treatment
episodes affect the persistence of individual medications and may
impact the outcomes and conclusions of a persistence study. It is
critical, therefore, to carefully consider the analysis criteria and
the use of sensitivity analysis with multiple data-cutting scenar-
ios in order to provide a better understanding of the data.
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OBJECTIVES: To develop a stochastic multi-domain micro-
simulation model for evaluation of cost-effectiveness and long-
term outcome in Alzheimer’s disease. METHODS: Key disease
indicators (e.g. cognitive function, functional abilities—ADLs
and care setting) were simulated over time for individual patients
using regression functions derived from longitudinal observa-
tional data. Micro-simulation of each individual patient enables
incorporating individual variability over time into the model, i.e.
the disease progression depends on individual characteristics and
previous progression rates. The disease indicators together with
patient characteristics were used to predict the need for health
care services and ultimately the need for full time care.
RESULTS: The model simulated individual patients estimating
cognitive function, physical function, resource utilization and
care setting for each 6 months period until the event of death.
Average disease progression rates and estimated resource use
well corresponded to what have been observed in clinical praxis.
CONCLUSION: Existing models stratify patients into artiﬁcial
cohorts using single domains (typically either cognition or care
setting) thereby neglecting important explanatory variables and
limiting the extent to which individual variability can be
modeled. The proposed model provides a dynamic simulation
framework completely based on regression functions. This
enables inclusion of all relevant disease indicators and incorpo-
ration of individual variability into disease progression func-
tions. The proposed model can be used for economic evaluation
of any treatment intervention.
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OBJECTIVES: To compare 12-month outcomes in patients with
schizophrenia who received risperidone long-acting injectable
(RLAI) treatment and are enrolled in the electronic-Schizophre-
nia Treatment Adherence Registry (e-STAR) in Spain (SP), Aus-
tralia (AU), and Belgium (BE). METHODS: E-STAR is a secure,
web-based, international, long-term observational study of
patients with schizophrenia who commence RLAI treatment.
Data are collected both retrospectively and prospectively. Reason
for initiating RLAI and treatment discontinuation data were col-
lected. RESULTS: A total of 2498 patients (SP = 1332, AU =
763, BE = 403) were included in this analysis. At 12-months,
84% (CI = 81.5–86.2), 52.2% (CI = 48.2–56.0), and 71.6% (CI
= 65.3–77.1) of patients in Spain, Australia and Belgium were
still being maintained on RLAI respectively. The three most
common reasons reported for discontinuing RLAI was “insufﬁ-
cient response”, “choice”, and “lost to follow-up”. The most
important reason reported for initiating RLAI was “compliance”
in Australia and Belgium (AU = 52%, BE = 43%). In Spain it
was “insufﬁcient response” (33%) followed closely by compli-
ance (32%). The differences seen in the results may partially be
due to differences in the baseline characteristics of the patients.
The age of patients at baseline was signiﬁcantly different (SP =
38.3, AU = 37.1, BE = 39.9; p = 0.0005). Time since diagnosis
(in years) was signiﬁcantly higher in Spain than Australia and
Belgium (SP = 12.6, AU = 10.6, BE = 9.3; p < 0.0001). Spanish
patients had signiﬁcantly higher baseline GAF scores than the
Australian and Belgian patients (SP = 46.8, AU = 42.6, BE = 44;
p < 0.0001). The proportion of inpatients was signiﬁcantly dif-
ferent between the three countries (SP = 9.2%, AU = 51.6%, BE
= 55.6%; p < 0.0001). Finally, the proportion of patients
employed (full-time and part-time) was also signiﬁcantly differ-
ent (SP = 12.7%, AU = 8.5%, BE = 15.4%; p < 0.0008). Due to
these differences, data were not pooled. CONCLUSION: This
interim analysis shows that the majority of patients were still
maintained on RLAI at 12-months. However, the discontinua-
tion rates of RLAI were signiﬁcantly different between countries.
This may partially be due to differing baseline patient charac-
teristics in the countries.
